EICHOR
● Recruiting
Investigational Trial to Evaluate Safety and Tolerability of Treprostinil in Children Diagnosed With PAH
Condition: Pulmonary Arterial Hypertension · Sponsor: AOP Orphan Pharmaceuticals AG
About this study
The goal of this clinical trial is to evaluate safety and tolerability of preservative-free parenteral treprostinil in paediatric patients with PAH (PH Group 1) who are below 18 years of age. The main question it aims to answer is: • if preservative-free parenteral treprostinil is safe and tolerable in the treatment of paediatric PAH in patients who are either prostacyclin-naïve or have been previously treated with commercially available parenteral treprostinil formulations. Participants will receive either subcutaneous (SC) or intravenous (IV) preservative-free treprostinil and will be observed for 5 months (20 weeks ± 1 week).
This description comes directly from the study's public registry record.
Talk to the study team
Clinical Project Manager · 4366488375206 · trepaed@aop-health.com
Always discuss trial participation with your own doctor first.
Locations (5)
| Medizinische Universität Wien | Vienna, State of Vienna, Austria | Recruiting |
| Necker-Enfants Malades Hospital, Paris | Paris, Paris, France | Recruiting |
| Gottsegen National Cardiovascular Center | Budapest, Budapest, Hungary | Recruiting |
| Pediatric Cardiac Center | Bratislava, Slovakia | Recruiting |
| Ramón y Cajal University Hospital | Madrid, Madrid, Spain | Recruiting |
Follow this study
Save your interest here for when the public record changes — results posted, or the study's status changes. Email alerts for this study aren't switched on yet.
We keep this only about this public record, and never email you without alerts being switched on. Want it removed at any time? Email hello@eichor.com. Never medical advice. By subscribing you agree to our Terms of Use and Privacy Policy.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT06350032